Cogent Biosciences, Inc. research snapshot
COGT AI stock analysis currently sees Cogent Biosciences as a pre-commercial biotechnology company with three New Drug Applications under FDA review for bezuclastinib: GIST in combination with sunitinib under Priority Review with a PDUFA date of November 30, 2026, NonAdvSM with a PDUFA date of December 30, 2026, and Advanced Systemic Mastocytosis submitted on June 30, 2026. At the August 3, 2026 cutoff, COGT traded near $39.50 with a verified market capitalization of $6.75 billion. The core tension is that the clinical data from the APEX, PEAK and SUMMIT trials are strong and the company targets its first approvals in Q4 2026, while the company has zero product revenue, a trailing twelve-month net loss of approximately $329 million, $866 million of cash and investments offset by $223 million of long-term debt, and no commercial track record yet. This page is informational only and not investment advice.
Current price
$39.50
Market cap
$6.75 billion
AI score
46 / 100
Rating
Three bezuclastinib NDAs are under FDA review with a Q4 2026 approval target, but the company remains pre-revenue with binary regulatory and commercial risk
Trend status
Above the 20-day, 50-day and 200-day moving averages, about 10% below the 52-week high after a pullback from the July peak
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Cogent is a pre-revenue precision oncology company developing bezuclastinib for genetically defined diseases. Business quality is still unproven: no approved products, no revenue, and no commercial infrastructure yet. Clinical execution has been strong with three NDA submissions in about six months, but business quality cannot be assessed until there is a commercial track record. | Low |
| Moat | The moat is hypothetical. Bezuclastinib targets KIT exon 17 mutations with selectivity that differentiates it from older multikinase inhibitors, and the PEAK combination showed a 0.50 hazard ratio versus sunitinib alone. If approved, patents, regulatory exclusivity, manufacturing know-how, and prescriber relationships could create barriers, but the moat remains narrow until commercial scale is achieved. | Low |
| Management | CEO Andrew Robbins and the management team have guided bezuclastinib through three pivotal trials and three NDA submissions. The next capital-allocation test is balancing commercial launch investment, pipeline expansion, and cash management to reach profitability without excessive dilution, especially after adding $223 million of long-term debt in FY2025. | Medium |
| Financial trend | COGT has zero revenue and a widening net loss trajectory: -$256 million in FY2024, -$329 million in FY2025, and a -$97 million loss in Q1 2026 alone. Operating cash use was -$264 million in FY2025 and -$87 million in Q1 2026. The trend is deteriorating and will continue until product revenue begins. | High |
| Valuation | At $39.50, COGT has a $6.75 billion market cap with zero revenue and negative earnings. P/E and P/S are not meaningful. P/B is about 10.1x, reflecting the market pricing future commercial cash flows rather than current book value. The $866 million of cash and investments minus $223 million of long-term debt leaves about $643 million of net cash, or roughly 18 to 24 months of runway at current burn rates. | Medium |
| Technical trend | COGT traded at $39.50 on the August 3, 2026 cutoff, about 10% below its 52-week high of $43.73 and far above its 52-week low of $10.38. The stock is above its 20-day, 50-day and 200-day moving averages, with 14-day RSI near 53 after a pullback from overbought levels in July, consistent with a consolidating uptrend driven by NDA milestones. | Medium-high |
| Risk level | Risk is very high. COGT faces binary FDA decisions across three indications (GIST PDUFA November 30, 2026, NonAdvSM PDUFA December 30, 2026, and AdvSM under review), commercial launch execution, pricing and reimbursement uncertainty, competition from approved therapies, cash burn, $223 million of debt, and clinical-stage pipeline risk. | High |
| AI confidence | Reported financial, clinical, and FDA event data are well documented, but AI cannot know FDA decisions, labeling, pricing, market adoption, or the outcome of future trials. | High data confidence |
| Investment certainty | Investment certainty is low because the entire valuation depends on regulatory approvals and commercial adoption of a drug that has not yet been approved or sold. The wide range of analyst price targets ($20 to $67) illustrates the uncertainty. | Low |
COGT AI stock forecast
The COGT AI stock forecast uses scenarios instead of a promised price. Because COGT is pre-revenue with no positive EPS, the three-year model uses illustrative peak sales assumptions for bezuclastinib across GIST, NonAdvSM, and AdvSM, with probability-adjusted net present value. These scenarios are valuation frameworks, not predictions, because FDA decisions, labeling, pricing, market share, and competition remain highly uncertain.
$55 to $70
More likely if bezuclastinib is approved in GIST (PDUFA November 30, 2026) and NonAdvSM (PDUFA December 30, 2026) with broad labels, the AdvSM NDA also advances, pricing supports meaningful peak sales, commercial launch execution is strong, reimbursement is secured, and the cash position is managed without dilutive financing. JPMorgan holds a $67 target and Wedbush and HC Wainwright hold $55 targets.
$35 to $48
More likely if at least one or two indications are approved with moderate labels, initial commercial uptake is steady but not exceptional, competition from approved therapies limits market share, and ongoing cash burn requires some additional financing. This range brackets the $45.90 consensus analyst target.
$15 to $25
More likely if a Complete Response Letter or significant label limitation delays or restricts approval in one or more indications, clinical data are questioned, pricing or reimbursement disappoints, competition captures more share than expected, or cash burn plus the $223 million debt balance forces dilutive financing that transfers value away from current shareholders.
COGT AI technical analysis
COGT AI technical analysis uses the August 3, 2026 Barchart and MarketBeat market snapshots. The static page does not fetch live market data. The price reference of $39.50 was above the 20-day ($39.48), 50-day ($36.64) and 200-day ($34.86) moving averages, about 10% below the 52-week high, with 14-day RSI near 53 after pulling back from the July high, indicating a consolidating uptrend supported by FDA milestones.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $39.50 | MarketBeat quote snapshot on August 3, 2026, used for the analysis and market-cap calculation. The stock opened the year near $35.52. |
| Near support | $36.60 to $37 | The 50-day moving average area ($36.64). A live chart should confirm whether this zone holds on pullbacks. |
| Secondary support | $34.90 | The 200-day moving average ($34.86), which sits well below the current price and marks the longer-term trend line. |
| 52-week high resistance | $43.73 | The July high. A sustained breakout above this level would open a new price range toward analyst targets near $45.90. |
| Momentum | RSI near 53 | Barchart reported 14-day RSI of 53.11 on the cutoff. The stock pulled back from an overbought July reading above 70, easing momentum risk. |
| Volume | About 2.2 million average shares | MarketBeat reported average volume of 2.23 million shares, with Barchart 50-day average volume near 2.6 million. Volume spikes around FDA and clinical milestones. |
| Volatility | Beta 0.38, 14-day historic volatility near 45% | Reported beta was below one, but binary biotech events can produce sharp gaps and the measured 14-day historic volatility near 45% is elevated. |
| Short interest | 10.37% of float | Short interest of 10.37% of the float with a 6.7 day days-to-cover reading reflects elevated bearish positioning that can add volatility around binary events. |
| Invalidation | Sustained close below $36.60 | A sustained close below the 50-day moving average area would weaken the uptrend and should trigger a review of fundamentals and FDA timeline. |
COGT AI trading strategy
The COGT AI trading strategy is a research and risk-control framework, not a personalized recommendation. It combines live chart confirmation with PDUFA milestones, clinical data events, Q2 2026 earnings on August 4, 2026, cash and debt updates, and financing announcements.
COGT is driven by binary regulatory and clinical events. The next major catalysts are the GIST PDUFA date of November 30, 2026, the NonAdvSM PDUFA date of December 30, 2026, Q2 2026 earnings on August 4, 2026, and continued FDA review of the AdvSM NDA. Monitor NDA review progress, FDA advisory committee meetings, and any clinical data updates.
Binary event risk means position sizing must account for the possibility of large gap moves in either direction. Tight stops are unreliable around FDA decisions.
If COGT holds above the 50-day moving average near $36.60 to $37 and resumes its climb toward the $43.73 high, a trend-following approach can be considered. Confirm price action with positive regulatory progress and no cash runway deterioration.
A sustained close below the 50-day average or a failed PDUFA event would invalidate the trend. Size for gap risk rather than relying on a tight stop.
Track the GIST and NonAdvSM PDUFA timelines, FDA labeling decisions, the AdvSM NDA review, commercial launch plans, cash and investment balance, the $223 million debt balance, operating burn rate, any new equity or debt financing, bezuclastinib pricing in approved indications, and competitor developments.
Reduce confidence if cash burn accelerates without a corresponding increase in near-term approval probability, if the FDA issues a CRL in any indication, or if dilutive financing is announced at unfavorable terms.
Investment research summary
Cogent Biosciences is a precision oncology company developing bezuclastinib, a selective KIT inhibitor, for genetically defined diseases across three pivotal programs: Gastrointestinal Stromal Tumors (GIST), non-advanced systemic mastocytosis (NonAdvSM), and Advanced Systemic Mastocytosis (AdvSM). Customers and payers will pay if the drug is approved, gains favorable labeling, achieves broad reimbursement, and demonstrates superior efficacy or tolerability versus existing therapies.
The moat is potential rather than proven. If approved, bezuclastinib would benefit from regulatory exclusivity, patent protection, selective KIT inhibition differentiated from multikinase inhibitors, Breakthrough Therapy Designation in GIST, and first-mover data in NonAdvSM. The moat can narrow if competing KIT inhibitors, improved therapies, or generics enter the market.
The thesis fails if the FDA issues a Complete Response Letter or significantly narrows the label in any of the three indications, if pricing or reimbursement is unfavorable, if commercial launch execution is slow, if competition erodes market share, if cash burn plus the $223 million debt balance requires dilutive financing, or if earlier-stage pipeline candidates fail in clinical trials.
Management has advanced bezuclastinib through three pivotal trials and three NDA submissions in roughly six months under CEO Andrew Robbins. The capital-allocation test ahead is whether launch investment, R&D spending, and cash management can reach profitability without excessive shareholder dilution, especially after the FY2025 debt raise and $700 million of equity issuance.
Precision oncology and targeted therapy for genetically defined diseases represent a lasting industry trend. GIST, NonAdvSM, and AdvSM all have established treatment paradigms with room for improved therapies. The opportunity is real but constrained by patient population sizes, pricing pressure, and competition from both approved and pipeline therapies.
The market is pricing COGT at $6.75 billion based on expected future approval and commercial cash flows across three indications rather than current earnings or revenue. Margin of safety is limited until approval, label, pricing, and initial commercial data provide concrete evidence of the revenue trajectory.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| COGT price | $39.50 | MarketBeat quote snapshot | August 3, 2026 |
| Market capitalization | $6.75 billion, verified as $39.50 x 170.87 million shares (0.01% deviation) | financial_rigor.py and MarketBeat | August 3, 2026 |
| Cash and investments | $866 million at March 31, 2026 ($241M cash + $625M short-term investments) | MarketBeat financials (balance sheet) | August 3, 2026 |
| Long-term debt | $223 million at March 31, 2026; net cash of about $643 million | MarketBeat financials (balance sheet) | August 3, 2026 |
| FY2025 net loss | -$329 million, widening from -$256 million in FY2024; FY2025 operating cash use -$264 million | MarketBeat financials (income statement) and SEC filings | August 3, 2026 |
| Q1 2026 net loss | -$97 million; operating cash use -$87 million for the quarter ended March 31, 2026 | MarketBeat financials (income statement and cash flow) | August 3, 2026 |
| Shares outstanding | 170.87 million at March 31, 2026 | MarketBeat financials | August 3, 2026 |
| Valuation math | P/E and P/S are not meaningful with negative TTM EPS and no revenue; P/B about 10.1x; TTM EPS -$2.17; TTM net income -$328.94 million | financial_rigor.py valuation verification and MarketBeat | August 3, 2026 |
| Technical inputs | 52-week range $10.38 to $43.73, 20/50/200-day MAs $39.48/$36.64/$34.86, 14-day RSI 53.11, average volume 2.23M, short interest 10.37% of float | Barchart and MarketBeat statistics | August 3, 2026 |
| Analyst consensus | Moderate Buy, 13 analysts (2 strong buy, 8 buy, 2 hold, 1 sell), price target range $20.00 to $67.00, consensus $45.90 | MarketBeat analyst forecasts | August 3, 2026 |
| FDA milestones | GIST NDA under Priority Review, PDUFA November 30, 2026; NonAdvSM NDA accepted, PDUFA December 30, 2026; AdvSM NDA submitted June 30, 2026; Breakthrough Therapy Designation in GIST | MarketBeat FDA events and GlobeNewswire | August 3, 2026 |
This COGT AI stock analysis page is an informational research tool only. It is not investment advice, financial advice, tax advice, a recommendation, or a promise of future returns. Forecast ranges are scenarios based on available public filings, clinical trial disclosures, FDA event reports, quote snapshots, technical data, and third-party sources as of August 3, 2026. They may be wrong, incomplete, or outdated after new clinical data, FDA decisions, commercial updates, financing events, market moves, or macro conditions.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
